title: Interferon therapy for the anti-HBe positive form of chronic hepatitis B.
abstract: Two distinct serologic types of chronic hepatitis B have been identified, namely the "classical" HBeAg positive form and the "atypical" HBeAg negative, anti-HBe positive variant which is due to infection by a mutant HBV having a pre-core stop codon that makes the virus unable to produce HBeAg. The anti-HBe positive form is currently the prevalent type of chronic hepatitis B in the Mediterranean area, being associated with a more severe clinical course compared to HBeAg positive cases. The response to interferon therapy in patients with anti-HBe positive chronic hepatitis B has been recently investigated in control trials. These studies have shown that normalization of ALT with efficient suppression of virus activity can be achieved in 50-80% of patients while treated with interferon alpha indicating that also the pre-core mutant of HBV is sensitive to the antiviral effect of interferon. However, reactivation of hepatitis occurs in a variable percentage of initial responders when interferon is stopped. The probability of reactivation increases when the disease is of long duration, when cirrhosis is present and particularly if the pre-core mutant of HBV has become the predominant type of circulating virus, indicating that this HBV variant is more resistant to immunoclearance compared to wild type HBV.
authors.affiliation: Clinica Medica II, University of Padova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Alberti
authors.forename: G
authors.initials: G
authors.lastname: Fattovich
mesh_terms: D002908:Chronic Disease / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000097:blood; D006509:Hepatitis B / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000235:genetics; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008099:Liver / Q000033:anatomy & histology; D011379:Prognosis
chemical_list: D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; D007372:Interferons